Guideline Video
Guideline Resources
- Title: Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients
- Society: Infectious Diseases Society of America
- Publish Date: October 17, 2025
- Summary
- Patient Summary
- Full-text
Video Transcription
Just published October 17th, 2025 - The Infectious Diseases Society of America’s guideline on Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients.
The objective of this guideline is to address patients who have a hematologic malignancy, primary immunodeficiency, autoimmune disease treated with immunosuppressants or biologics, or HIV with severe immunosuppression, as well as patients who are recipients of solid organ transplants (SOT), hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell therapy (CAR-T), or solid-tumor chemotherapy.
There is 1 recommendation and 5 remarks so let’s get started.
In adults and children with compromised immunity, the IDSA guideline recommends administering age-appropriate 2025-2026 COVID-19 vaccinations
On to the remarks,
- An FDA-approved 2025-2026 COVID-19 vaccine dose should be given as soon as possible.
- A second dose of COVID-19 vaccination is likely to extend protection.
- For never vaccinated and incompletely vaccinated patients refer to published guidelines.
- Household members and close contacts of immunocompromised patients should be up to date with COVID-19 vaccination.
- It is appropriate for patients to receive COVID-19, influenza, and RSV vaccines together.
Make sure to check out the full guideline from Infectious Diseases Society of America and other related clinical decision support tools at guidelinecentral.com.
Copyright © 2025 Guideline Central, all rights reserved.